SCHEMBL12092238

SCHEMBL12092238

CC(C)(C)CN1CCN(C(=O)CCC(=O)ON2C(=O)CCC2=O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 1/20 0.36
▸ LMNA P02545 4/20 0.34
▸ TSHR P16473 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ DDB1 Q16531 1/20 0.32
▸ CRBN Q96SW2 1/20 0.32
▸ MGLL Q99685 1/20 0.31
▸ SIGMAR1 Q99720 2/20 0.31
▸ FDFT1 P37268 1/20 0.30
▸ KDM4E B2RXH2 2/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ USP2 O75604 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30
▸ HTR1A P08908 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12092254 0.85 TACR1 (0.33) TACR1HSD11B1
SCHEMBL16330527 0.83 ALDH1A1 (0.39) LMNATSHRPOLBALDH1A1CYP3A4
SCHEMBL12092237 0.82 ALDH1A1 (0.32) TSHRALDH1A1CYP3A4
SCHEMBL32682848 0.82 DDB1 (0.49) LMNAALDH1A1DDB1CRBNKDM4E
SCHEMBL12092240 0.81 TACR1 (0.30) TACR1
SCHEMBL19698164 0.79 CYP2D6 (0.37) LMNATSHRPOLBALDH1A1HSD11B1
SCHEMBL12092235 0.79 MEN1 (0.34) LMNAPOLBALDH1A1KDM4EMEN1
SCHEMBL19703782 0.77 NPC1 (0.53) LMNAALDH1A1MEN1HPGDKMT2A
SCHEMBL9925280 0.76 PLA2G10 (0.34) ALDH1A1KDM4E
SCHEMBL21664525 0.76 POLB (0.55) LMNATSHRPOLBALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952147-B2 Conjugates, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-02-10 — — US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF ERG28, CARS1, FOLH1 TACR1 2508/4885LMNA 2220/4885TSHR 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback